Wei Chen

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 11

Top Topics

End Stage Renal Disease

Peritoneal Dialysis

Ejection Fraction

Acute Lymphoblastic Leukemia

Top Venues

Nature communications

Hematology (Amsterdam, Netherlands)

Journal of oncology

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Yuekun Qi, Hujun Li, Kunming Qi, Feng Zhu, Hai Cheng, Wei Chen, Zhiling Yan, Depeng Li, Wei Sang, Xiaoming Fei, Weiying Gu, Yuqing Miao, Hongming Huang, Ying Wang, Tingting Qiu, Jianlin Qiao, Bin Pan, Ming Shi, Gang Wang, Zhenyu Li, Junnian Zheng, Kailin Xu, Jiang Cao
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. American journal of hematology (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Huimin Chen, Ruixue Ma, Qianqian Zhang, Fengyi Lu, Yuhan Ma, Jingxin Zhou, Jiang Cao, Kunming Qi, Zhiling Yan, Wei Sang, Feng Zhu, Haiying Sun, Depeng Li, Zhenyu Li, Hai Cheng, Kailin Xu, Wei Chen
The prognostic significance of POD24 in peripheral T-cell lymphoma. Hematology (Amsterdam, Netherlands) 29 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ruixue Ma, Qi Zhang, Yang Liu, Hujun Li, Huimin Chen, Qianqian Zhang, Jianlin Qiao, Kunming Qi, Guifang Shen, Cai Sun, Xuguang Song, Jiang Cao, Hai Cheng, Feng Zhu, Zhiling Yan, Wei Sang, Depeng Li, Haiying Sun, Junnian Zheng, Zhenyu Li, Kailin Xu, Wei Chen
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma. Clinical and experimental medicine 24 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Huimin Chen, Ruixue Ma, Qianqian Zhang, Fengyi Lu, Yuhan Ma, Jingxin Zhou, Jiang Cao, Kunming Qi, Zhiling Yan, Wei Sang, Feng Zhu, Haiying Sun, Depeng Li, Zhenyu Li, Hai Cheng, Kailin Xu, Wei Chen
The prognostic significance of POD24 in peripheral T-cell lymphoma. Hematology (Amsterdam, Netherlands) 29 (1) (2024)
Jieyun Xia, Hujun Li, Zhiling Yan, Dian Zhou, Ying Wang, Yuekun Qi, Jiang Cao, Depeng Li, Hai Cheng, Wei Sang, Feng Zhu, Haiying Sun, Wei Chen, Kunming Qi, Dongmei Yan, Tingting Qiu, Jianlin Qiao, Ruosi Yao, Yang Liu, Xue Wang, Yanlei Zhang, Shuixiu Peng, Chih-Hua Huang, Junnian Zheng, Zhenyu Li, Alex H Chang, Kailin Xu
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Qianqian Zhang, Ruixue Ma, Huimin Chen, Wentong Guo, Zhenyu Li, Kailin Xu, Wei Chen
CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression. Journal of oncology 2023 (2023)